Valeant Pharmaceuticals International Stock Gaps Up On Today's Open (VRX)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Shares of Valeant Pharmaceuticals International (NYSE: VRX) were gapping up Tuesday morning with an open price 12.1% higher than Friday's closing price. The stock closed at $51.27 Friday and opened today's trading at $57.45.

The average volume for Valeant Pharmaceuticals International has been 1.7 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $15.58 billion and is part of the health care sector and drugs industry. Shares are up 9.8% year to date as of the close of trading on Friday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. The company has a P/E ratio of 269.8, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and generally higher debt management risk. You can view the full Valeant Pharmaceuticals International Ratings Report.

Get more investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year

Beleaguered Hedge Fund Titan Bill Ackman Is Having Another Rough Year